About the project
Despite ongoing efforts, malaria remains a significant health challenge, particularly for young children in sub-Saharan Africa. Recognizing the disproportionate burden of malaria among children under the age of five, the World Health Organization (WHO) recommended Intermittent Preventive Treatment for Infants (IPTi) in 2010. This strategy involved administering antimalarial medication to infants during routine immunization visits. While IPTi has shown promise in reducing malaria-related illness, its implementation has been limited. To address this, the WHO expanded the recommendation in 2022 to include children up to two years of age and renamed the intervention Perennial Malaria Chemoprevention (PMC).
Progress
MULTIPLY will carry out a before-after evaluation of the impact of PMC delivered through the project. PMC will be delivered at health facilities and mobile-outreach EPI clinics to all children living in the project districts. The number of PMC doses a child will receive will be based on the EPI schedule of the country, with a maximum of 6 doses given in the first two years of life. In order to assess the impact of the intervention a number of baseline / pre-intervention studies will be conducted to measure malaria incidence, malaria hospitalisation, and other indicators in this population.
Where we are
×
![]()
